Research on sonoactivatable nanoparticles funded by EuroNanoMed II ERA-NET program
Qian Peng at the Department of Pathology has received funding for 5,5 million NOK from the joint action of the Norwegian Research Council’s NANO2021 programme and ERA-NET platform that comprises 20 partners from 17 countries/regions through the European Commission’s 7th Framework Programme. The project, named SonoTherag, is coordinated by a French organization and Qian Peng together with Petras Juzenas is a partner in this project. This project has started in 2015 and will last until 2018.
The goal of this project is to develop a nanotechnology allowing ultrasound-mediated targeted delivery and controlled cytotoxicity of sonosensitising agents while monitoring the process through 19F MRI and/or ultrasound imaging. The project will employ high intensity focused ultrasound (HIFU) for cancer treatment. Focused ultrasound beam is used to release the encapsulated sonosensitiser at the tumor site and further activate the sonosensitiser to generate free radicals that induce tumor destruction. The 19F MRI is used to monitor the nanoparticle location and to quantify the drug delivery process.
In addition to OUS, the partners include
- University of Avignon, France
- French National Centre for Scientific Research, CNRS, Nancy, France
- University of Geneva, Switzerland
- Intelligence in Medical Technologies, Paris, France